ManiD.R., KrugK., ZhangB., et al.Cancer proteogenomics: current impact and future prospects. Nature Reviews Cancer, 22(5):298–313 (2022).
2.
RodriguezH., ZenklusenJ.C., StaudtL.M., et al.The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell, 184(7):1661–1670. (2021).
3.
ZhangB., WhiteakerJ.R., HoofnaagleA.N., et al.Clinical potential of mass spectrome try-based proteogenomics. Nature Reviews Clinical Oncology, 16(4):256–268. (2019).
4.
HerbstS.A., VerterlundM., HelmboltA.J., et al.Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nature Communications, 13:6226 (2022).
5.
LehtiöJ., ArslanT., SiavelisI., et al.Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2:1224–1242 (2021).
6.
HuangD., SavageS.R., CalinawanA.P., et al.A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 40(46):6395–6405 (2021).
7.
HuangD., ChowdhuryS., WangH.I., et al.Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Reports Medicine, 2(12):100471 (2021).
8.
DonovanM.K.R., HuangY., BlumeJ.E., et al.Peptide-centric analyses of human plasma enable increased resolution of biological insights into non-small cell lung cancer relative to protein-centric analysis. BioRxiv (2022). https://doi.org/10.1101/2022.01.07.475393.
